COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03198884
Recruitment Status : Completed
First Posted : June 26, 2017
Results First Posted : July 7, 2020
Last Update Posted : July 7, 2020
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
John Verna, Southern Illinois Healthcare Foundation

Brief Summary:
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

Condition or disease Intervention/treatment
HIV-1-infection Drug: Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : April 18, 2018
Actual Study Completion Date : May 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. HIV RNA Quantitative Testing (Serum) [ Time Frame: 48 weeks ]
    Our first primary endpoint evaluated the percent of study subjects with an RNA <50 copies/mL at 48 weeks after initiation of the once daily two-drug regimen.

  2. The Change in Serum Creatinine From Baseline to 48 Weeks. [ Time Frame: 48 weeks ]
    A second primary endpoint was evaluating the change in serum creatinine from baseline to 48 weeks for all subjects.

Secondary Outcome Measures :
  1. Change in Mean CD4+ Cell Count From Baseline. [ Time Frame: 48 weeks ]
    A secondary endpoint included changes from baseline in CD4+ cell counts.

  2. Incidence of Adverse Events. [ Time Frame: 48 weeks ]
    10 study subjects reported an adverse event.

  3. Number of Grade 1 Adverse Events Reported [ Time Frame: 48 weeks ]

    10 study subjects reported adverse events. All adverse events reported (insomnia, diarrhea, headache) were of Grade 1 severity.

    There were no adverse events that led to discontinuation of the study regimen.

  4. Analysis of RNA at Time Points 24, 36 and 48 Weeks. [ Time Frame: 48 weeks ]

    This secondary outcome measure analyzed the percentage of subjects with < 50 copies/mL RNA at time points 24, 36 and 48 weeks.

    The percent of subjects with an RNA < 50 copies/mL at each time point was analyzed using McNemar's test following the guidelines of the Snapshot algorithm. Missing RNA data was considered a treatment failure.

  5. Analysis of Creatinine Clearance at Time Points 24, 36 and 48 Weeks. [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult HIV positive patients

Inclusion Criteria:

  • ≥18 years old
  • Received a regimen of darunavir 800 mg/ritonavir 100 mg in combination with dolutegravir 50 mg QD for ≥24 weeks as documented in EMR
  • Laboratory reports (CD4, viral load, SrCr) available at time points +/- 4 6 weeks from 12, 24, 36, 48 weeks from start of regimen
  • Resistance data (if applicable)

Exclusion Criteria:

  • Received a regimen of darunavir/ritonavir in combination with dolutegravir for <24 weeks duration
  • Patients receiving darunavir/ritonavir + DTG+NRTI's
  • Missing laboratory data in ≥2 study time points
  • Patients missing more than five doses over two weeks prior study visit
  Study Documents (Full-Text)

Documents provided by John Verna, Southern Illinois Healthcare Foundation:
Layout table for additonal information
Responsible Party: John Verna, Physician Assistant, Southern Illinois Healthcare Foundation Identifier: NCT03198884    
Other Study ID Numbers: 16-1108-100C
First Posted: June 26, 2017    Key Record Dates
Results First Posted: July 7, 2020
Last Update Posted: July 7, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to share.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors